ALXO biotech catalysts & pipeline

ALX ONCOLOGY HOLDINGS INC · Data as of 2026-10-25

Upcoming catalysts

ALX2004 — Interim data

H2 2026

Enrollment continues in the dose-escalation portion of the Phase 1 trial of ALX2004, a novel antibody-drug conjugate (ADC) for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors, and is on track to report safety data in the second half of 2026.

Source filing

evorpacept — Topline data

mid-2027

– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer –

Source filing

Explore the free biotech catalyst calendar